代谢相关脂肪性肝病诊断与治疗研究进展#br#

doi:10.13438/j.cnki.jdzk.2022.04.014

摘要/Abstract

摘要：代谢相关脂肪性肝病是目前世界上最常见的慢性肝病，也是我国第一大肝病.其发病率呈逐年上升趋势，肝脏脂肪变性程度的加重，增加了肝脏纤维化、肝硬化甚至肝癌的发病率，严重危害人们的身体健康.近年来在MAFLD的诊断及治疗方面发生了许多新变化，已成为研究热点.本研究从脂肪肝的全球危害及卫生负担、脂肪肝命名的变迁、代谢相关脂肪性肝病的诊断与治疗几个方面展开综述，以期为代谢相关脂肪性肝病的早期诊断、病情评估、新药研发等提供参考.

关键词： 代谢相关脂肪性肝病, 非酒精性脂肪性肝病, 诊断, 治疗

Abstract: Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world and also the number one liver disease in China.Its incidence rate shows an upward trend year by year.If the degree of liver steatosis is aggravated,liver fibrosis may occur and eventually lead to liver cirrhosis and even hepatocarcinoma.All these are serious hazards to people's health.In recent years,many new changes have taken place in the diagnosis and treatment of MAFLD,which has become a research hotspot.This article reviews the global harm and health burden of fatty liver disease,the change of fatty liver naming and the diagnosis and treatment of metaboli-associated fatty liver disease.The purpose of this study is to provide reference for the early diagnosis,disease evaluation and new drug development of metabolic-associated fatty liver disease.

Key words: metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, diagnosis, treatment

王子金, 李学锋, 向明钧, 欧芳波. 代谢相关脂肪性肝病诊断与治疗研究进展#br#[J]. 吉首大学学报（自然科学版）, 2022, 43(4): 81-86.

WANG Zijin, LI Xuefeng, XIANG Mingjun, OU Fangbo. Research Advances in Diagnosis and Treatment of Metabolic- Associated Fatty Liver Disease[J]. Journal of Jishou University(Natural Sciences Edition), 2022, 43(4): 81-86.

参考文献

[1] ZHANG Xinrong,WONG GRACE LAI-HUNG,WONG VINCENT WAI-SUN.Application of Transient Elastography in Nonalcoholic Fatty Liver Disease[J].Clin Mol Hepatol,2020,26(2):128-141.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957．
[3] 邵幼林,范建高.非酒精性脂肪性肝病的流行现状与危害[J].中华肝脏病杂志,2019,27(1):10-13.
[4] FAN Jiangao,KIM SEUNG-UP,WONG VINCENT WAI-SUN.New Trends on Obesity and NAFLD in Asia[J].Journal of Hepatology,67(4):862-873.
[5] YOUNOSSI ZOBAIR,TACKE FRANK,ARRESE MARCO,et al.Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis[J].Hepatology,2019,69(6):2672-2682.
[6] ZOU Ziyuan，FAN Jiangao．Incidence of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease[J].Journal of Hepatology,2020,73(1):214-216.
[7] ESLAM MOHAMMED,SANYAL ARUN J,GEORGE JACOB.MAFLD:A Consensus Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J].Gastroenterology,2020,158(7):1999-2014.
[8] ESLAM MOHAMMED,NEWSOME PHILIP N,SARIN SHIV K,et al.A New Definition for Metabolic Associated Fatty Liver Disease:An International Expert Consensus Statement[J].Journal of Hepatology,2020,73(1):202-209.
[9] ESTES CHRIS,ANSTEE QUENTIN M,ARIAS-LOSTE MARIA TERESA,et al.Modeling NAFLD Disease Burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the Period 2016-2030[J].Journal of Hepatology,2018,69(4):896-904.
[10] YOUNOSSI ZOBAIR M,BLISSETT DEIRDRE,BLISSETT ROBERT,et al.The Economic and Clinical Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the United States and Europe[J].Hepatology,2016,64(5):1577-1586.
[11] LI Jie,ZOU Biyao,YEO YEE HUI,et al.Prevalence,Incidence,and Outcome of Non-Alcoholic Fatty Liver Disease in Asia,1999-2019:A Systematic Review and Meta-Analysis[J].Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[12] OKANOUE TAKESHI,UMEMURA ATSUSHI,YASUI KOHICHIROH,et al.Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Japan[J].Journal of Gastroenterology and Hepatology,2011,26(Supplement s1):153-162.
[13 ]SARIN SHIV K,KUMAR MANOJ,ESLAM MOHAMMED,et al.Liver Diseases in the Asia-Pacific Region:A Lancet Gastroenterology & Hepatology Commission[J].Lancet Gastroenterol Hepatol,2020,5(2):167-228.
[14] 赵泽华,刘晓琳,范建高.重视非酒精性脂肪性肝病自然史的研究[J].中华肝脏病杂志,2017,25(2):81-84.
[15] 王梦雨,杨蕊旭,范建高.重视代谢相关脂肪性肝病的特征与预后临床研究[J].实用肝脏病杂志,2021,24(3):308-311.
[16] PAIK JAMES M,GOLABI PEGAH,YOUNOSSI YOUSSEF,et al.Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017:The Growing Impact of Nonalcoholic Fatty Liver Disease[J].Hepatology,2020,72(5):1605-1616．
[17] ESLAM MOHAMMED,SARIN SHIV K,WONG VINCENT WAI-SUN,et al.The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease[J].Hepatology International,2020,14(6):889-919.
[18] ZHANG Jianbin,LIN Shuangzhe,JIANG Daixi,et al.Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease:Conspirators or Competitors? [J].Liver International,2020,40(3):496-508.
[19] 范建高.非酒精性脂肪性肝病的研究现状与展望[J].临床肝胆病杂志,2015,31(7):999-1001.
[20] 黄磊杰,许炎煌,范建高.重视非酒精性脂肪性肝病异质性的临床研究[J].中华肝脏病杂志,2020,28(3):193-197.
[21] DUFOUR J F.Time to Abandon NASH? [J].Hepatology,2016,63(1):9-10.
[22] The Lancet Gastroenterology & Hepatology.Redefining Non-Alcoholic Fatty Liver Disease:What’s in a Name? [J].The Lancet Gastroenterology & Hepatology,2020,5(5):419.
[23] 金倩,黄磊杰,范建高.非酒精性脂肪性肝病的更名之争[J].西南医科大学学报,2020,43(2):93-96.
[24] SOFTIC S，KAHN C R.Fatty Liver Disease:Is it Nonalcoholic Fatty Liver Disease or Obesity-Associated Fatty Liver Disease? [J].European Journal of Gastroenterology & Hepatology,2019,31(1):143.
[25] 薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介[J].临床肝胆病杂志,2020,36(6):1224-1227.
[26] MNDEZ-SNCHEZ NAHUM,VALENCIA-RODRGUEZ ALEJANDRO.Caveats for the Implementation of Global Strategies Against Non-Alcoholic Fatty Liver Disease[J].Journal of Hepatology,2020,73(1):212-214.
[27] 肖倩倩,王梦雨,范建高.亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J].临床肝胆病杂志,2021,37(1):41-45．
[28] VILAR-GOMEZ EDUARDO,MARTINEZ-PEREZ YADINA,CALZADILLA-BERTOT LUIS,et al.Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis[J].Gastroenterology,2015,149(2):367-378.
[29] LASSAILLY GUILLAUME,CAIAZZO ROBERT,NTANDJA-WANDJI LINE-CAROLLE,et al.Bariatric Surgery Provides Long-Term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis[J].Gastroenterology,2020,159(4):1290-1301.
[30] SALOMONE FEDERICO,SHARAIHA REEM Z,BOKOSKI IVO.Endoscopic Bariatric and Metabolic Therapies for Non-Alcoholic Fatty Liver Disease:Evidence and Perspectives[J].Liver International,2020,40(6):1262-1268.
[31] BELFORT RENATA,HARRISON STEPHEN A,BROWN KENNETH,et al.A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis[J].The New England Journal of Medicine,2006,355(22):2297-2307.
[32] MEHTL JUHA,KHANFR HOUSSEM,BENNETT DIMITRI,et al.Pioglitazone Use and Risk of Bladder Cancer:A Systematic Literature Review and Meta-Analysis of Observational Studies[J].Diabetology International,2018,10(1):24-36.
[33] PORTILLO-SANCHEZ PAOLA,BRIL FERNANDO,LOMONACO ROMINA,et al.Effect of Pioglitazone on Bone Mineral Density in Patients with Nonalcoholic Steatohepatitis:A 36-Month Clinical Trial[J].Journal of Diabetes,2019,11(3):223-231.
[34] VILAR-GOMEZ EDUARDO,CALZADILLA-BERTOT LUIS,WONG VINCENT WAI-SUN,et al.Type 2 Diabetes and Metformin Use Associate with Outcomes of Patients with Nonalcoholic Steatohepatitis-Related,Child-Pugh a Cirrhosis-ScienceDirect[J].Clinical Gastroenterology and Hepatology,2021,19(1):136-145.
[35] ZHOU Jian,KE Yang,LEI Xuefeng,et al.Meta-Analysis:The Efficacy of Metformin and Other Anti-Hyperglycemic Agents in Prolonging the Survival of Hepatocellular Carcinoma Patients with Type 2 Diabetes[J].Annals of Hepatology,2020,19(3):320-328.
[36] POCKROS PAUL J,FUCHS MICHAEL,FREILICH BRADLEY,et al.CONTROL:A Randomized Phase 2 Study of Obeticholic Acid and Atorvastatin on Lipoproteins in Nonalcoholic Steatohepatitis Patients[J].Liver International,2019,39(11):2082-2093.
[37] HARRISON STEPHEN A,WONG VINCENT WAI-SUN,OKANOUE TAKESHI,et al.Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH:Results From Randomized Ph III STELLAR Trials[J].Journal of Hepatology,2020,73(1):26-39.
[38] TACKE FRANK.Cenicriviroc for the Treatment of Non-Alcoholic Steatohepatitis and Liver Fibrosis[J].Expert Opinion on Investigational Drugs,2018,27(3):301-311.

[1]	张汝江, 张运周, 高岱佺. 原发性中枢神经系统弥漫性大B细胞淋巴瘤诊疗进展[J]. 吉首大学学报（自然科学版）, 2021, 42(6): 54-61.
[2]	杨波, 关静文. US-CNB组织学诊断早期乳腺浸润性小叶癌的价值[J]. 吉首大学学报（自然科学版）, 2021, 42(5): 65-69.
[3]	张振中. 智能布线系统的近端串扰故障测试与诊断[J]. 吉首大学学报（自然科学版）, 2018, 39(4): 43-47.
[4]	韦建波，张栋柱，罗浩杰，谭惠，韦涛. 基于改进的RBF神经网络的配电网故障诊断模型[J]. 吉首大学学报（自然科学版）, 2018, 39(1): 54-58.
[5]	舒陵. 基于模糊数学的液压挖掘机故障诊断[J]. journal6, 2015, 36(3): 52-55.
[6]	马桂雨, 王雪丹, 万丹 . 基于遗传小波神经网络的变压器故障诊断[J]. journal6, 2013, 34(1): 51-55.
[7]	张松华, 陆秀令. 基于BP神经网络的柴油发动机故障诊断[J]. journal6, 2012, 33(4): 69-71.
[8]	邵向潮, 何永强, 蔡鹃, 谢宏. 基于RBF神经网络的温度传感器故障诊断[J]. journal6, 2010, 31(2): 79-82.
[9]	谢宏, 文志勇, 何怡刚, 井建华. 非线性模拟电路故障的BPNN诊断算法设计与实现[J]. journal6, 2009, 30(3): 62-65.
[10]	邹永红, 马志明, 陈品儒, 吴桂峰, 陈志成, 方毅敏. 胸水和血清CEA、ADA 联合检测对恶性和结核性胸腔积液的诊断价值[J]. journal6, 2008, 29(3): 125-128.
[11]	谢长焱, 何怡刚. 非线性电阻网络故障诊断中漏诊现象的消除[J]. journal6, 2006, 27(6): 53-55.
[12]	游青, 李阳, 田华. 经颅多谱勒对头痛头晕的诊断与评估[J]. journal6, 2004, 25(4): 89-90.
[13]	谢宏, 彭卫韶, 何怡刚. 非线性动态网络/系统（N/S）模型辨识与故障诊断[J]. journal6, 2004, 25(4): 4-9.
[14]	谢长焱. 模拟线性电路中故障元件存在范围的确定[J]. journal6, 2003, 24(4): 12-16.
[15]	谢宏, 何怡刚, 吴杰. 基于HAAR小波和BP神经网络的非线性电路故障诊断[J]. journal6, 2003, 24(4): 7-11.